| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 32 | 2024 | 5061 | 3.080 |
Why?
|
| Cachexia | 4 | 2020 | 161 | 2.420 |
Why?
|
| Mucin-1 | 7 | 2017 | 127 | 1.550 |
Why?
|
| Carcinoma, Pancreatic Ductal | 15 | 2024 | 1724 | 1.550 |
Why?
|
| Metabolome | 4 | 2020 | 344 | 1.530 |
Why?
|
| Metabolomics | 5 | 2021 | 478 | 1.220 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2023 | 1215 | 1.170 |
Why?
|
| Nanoparticles | 6 | 2023 | 554 | 1.080 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2021 | 3821 | 1.060 |
Why?
|
| Cell Line, Tumor | 34 | 2022 | 14551 | 1.050 |
Why?
|
| Chitosan | 1 | 2023 | 79 | 0.910 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2023 | 1648 | 0.910 |
Why?
|
| Glycolysis | 8 | 2021 | 519 | 0.840 |
Why?
|
| Cell Culture Techniques | 3 | 2022 | 598 | 0.840 |
Why?
|
| Macrophages | 3 | 2018 | 1304 | 0.820 |
Why?
|
| NADPH Oxidase 4 | 1 | 2020 | 23 | 0.760 |
Why?
|
| Acidosis | 2 | 2022 | 116 | 0.760 |
Why?
|
| Glucose | 9 | 2019 | 1248 | 0.730 |
Why?
|
| Sirtuin 1 | 1 | 2020 | 89 | 0.710 |
Why?
|
| Metal Nanoparticles | 1 | 2021 | 164 | 0.710 |
Why?
|
| Radiation-Protective Agents | 5 | 2013 | 128 | 0.710 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 269 | 0.710 |
Why?
|
| Mice | 42 | 2024 | 34495 | 0.700 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 301 | 0.680 |
Why?
|
| Hydrolases | 1 | 2019 | 123 | 0.670 |
Why?
|
| Aspartate Aminotransferase, Cytoplasmic | 2 | 2021 | 3 | 0.670 |
Why?
|
| Cellular Reprogramming | 2 | 2020 | 189 | 0.660 |
Why?
|
| Glutamine | 2 | 2017 | 299 | 0.650 |
Why?
|
| Muscle, Skeletal | 3 | 2020 | 1270 | 0.650 |
Why?
|
| Deoxycytidine | 4 | 2021 | 1353 | 0.630 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2022 | 810 | 0.630 |
Why?
|
| Pancreas | 4 | 2020 | 718 | 0.630 |
Why?
|
| alpha-Tocopherol | 3 | 2013 | 78 | 0.620 |
Why?
|
| Arginase | 1 | 2018 | 48 | 0.620 |
Why?
|
| Animals | 48 | 2024 | 59536 | 0.610 |
Why?
|
| Radiation Tolerance | 2 | 2018 | 629 | 0.600 |
Why?
|
| Mucins | 3 | 2007 | 285 | 0.600 |
Why?
|
| Polyethylene Glycols | 3 | 2019 | 615 | 0.590 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2018 | 261 | 0.590 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2019 | 204 | 0.580 |
Why?
|
| Neurites | 1 | 2016 | 63 | 0.570 |
Why?
|
| Whole-Body Irradiation | 3 | 2013 | 307 | 0.570 |
Why?
|
| Muscle Proteins | 1 | 2020 | 549 | 0.560 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 8873 | 0.560 |
Why?
|
| Signal Transduction | 16 | 2022 | 11965 | 0.560 |
Why?
|
| Silymarin | 1 | 2015 | 2 | 0.560 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 848 | 0.560 |
Why?
|
| Arginine | 1 | 2019 | 500 | 0.550 |
Why?
|
| Energy Metabolism | 3 | 2021 | 992 | 0.550 |
Why?
|
| Software | 1 | 2023 | 1321 | 0.550 |
Why?
|
| Adenocarcinoma | 8 | 2021 | 7789 | 0.540 |
Why?
|
| Muscle Fibers, Skeletal | 3 | 2020 | 116 | 0.520 |
Why?
|
| Cell Proliferation | 14 | 2021 | 7226 | 0.490 |
Why?
|
| Lipids | 2 | 2017 | 644 | 0.490 |
Why?
|
| CA-125 Antigen | 1 | 2015 | 226 | 0.490 |
Why?
|
| Gastrointestinal Diseases | 3 | 2019 | 589 | 0.480 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 1299 | 0.470 |
Why?
|
| Mice, Nude | 12 | 2021 | 4307 | 0.470 |
Why?
|
| Stress, Physiological | 1 | 2017 | 492 | 0.460 |
Why?
|
| Microfilament Proteins | 3 | 2021 | 487 | 0.450 |
Why?
|
| Nanotubes | 2 | 2022 | 28 | 0.440 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2011 | 82 | 0.410 |
Why?
|
| Chromatography, Liquid | 3 | 2018 | 342 | 0.400 |
Why?
|
| Gamma Rays | 5 | 2019 | 242 | 0.380 |
Why?
|
| Endocrine Disruptors | 2 | 2022 | 53 | 0.380 |
Why?
|
| Humans | 63 | 2024 | 261506 | 0.380 |
Why?
|
| Hippocampus | 1 | 2016 | 915 | 0.370 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2018 | 368 | 0.370 |
Why?
|
| Carrier Proteins | 4 | 2021 | 2022 | 0.370 |
Why?
|
| DNA Damage | 2 | 2021 | 1954 | 0.370 |
Why?
|
| Drug Carriers | 3 | 2023 | 327 | 0.370 |
Why?
|
| Actin Cytoskeleton | 2 | 2020 | 82 | 0.360 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3230 | 0.360 |
Why?
|
| Antioxidants | 4 | 2015 | 507 | 0.350 |
Why?
|
| Gene Knockdown Techniques | 3 | 2017 | 1077 | 0.350 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 14289 | 0.340 |
Why?
|
| Radiation Injuries | 4 | 2019 | 1411 | 0.340 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 2864 | 0.330 |
Why?
|
| Membrane Proteins | 2 | 2019 | 2819 | 0.330 |
Why?
|
| Single-Cell Analysis | 3 | 2022 | 470 | 0.330 |
Why?
|
| Podophyllum | 1 | 2008 | 1 | 0.330 |
Why?
|
| Picrorhiza | 1 | 2008 | 4 | 0.330 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 324 | 0.330 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1546 | 0.330 |
Why?
|
| Culture Media, Conditioned | 2 | 2019 | 260 | 0.310 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2008 | 48 | 0.310 |
Why?
|
| Poloxamer | 2 | 2019 | 15 | 0.310 |
Why?
|
| Spleen | 5 | 2020 | 676 | 0.300 |
Why?
|
| Particle Size | 3 | 2023 | 182 | 0.300 |
Why?
|
| Neoplasms | 7 | 2023 | 15193 | 0.290 |
Why?
|
| Oxidation-Reduction | 2 | 2020 | 717 | 0.290 |
Why?
|
| Cell Hypoxia | 2 | 2018 | 328 | 0.290 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 153 | 0.290 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 7222 | 0.280 |
Why?
|
| Cell Count | 2 | 2018 | 508 | 0.270 |
Why?
|
| Gold | 3 | 2022 | 270 | 0.270 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 376 | 0.270 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2018 | 1217 | 0.250 |
Why?
|
| Microscopy | 2 | 2023 | 182 | 0.250 |
Why?
|
| Transcription Factors | 6 | 2022 | 5270 | 0.250 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2024 | 28 | 0.240 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 15694 | 0.240 |
Why?
|
| Cell Line | 4 | 2022 | 5114 | 0.240 |
Why?
|
| Rhodamines | 1 | 2023 | 49 | 0.240 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 987 | 0.240 |
Why?
|
| Folic Acid Antagonists | 1 | 2023 | 45 | 0.230 |
Why?
|
| Antigens, Neoplasm | 2 | 2007 | 1506 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 6 | 2022 | 6942 | 0.230 |
Why?
|
| Aurora Kinase A | 1 | 2024 | 202 | 0.220 |
Why?
|
| Cell Membrane | 1 | 2006 | 850 | 0.220 |
Why?
|
| Taxoids | 2 | 2017 | 967 | 0.220 |
Why?
|
| Transfection | 3 | 2017 | 2944 | 0.220 |
Why?
|
| Oxidative Phosphorylation | 3 | 2020 | 253 | 0.210 |
Why?
|
| Mitochondria | 2 | 2019 | 1282 | 0.210 |
Why?
|
| Glucose Transporter Type 1 | 2 | 2019 | 61 | 0.210 |
Why?
|
| Apoptosis | 7 | 2023 | 7591 | 0.210 |
Why?
|
| Inhibin-beta Subunits | 1 | 2022 | 21 | 0.210 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2024 | 221 | 0.210 |
Why?
|
| Activins | 1 | 2022 | 98 | 0.210 |
Why?
|
| Protein Stability | 2 | 2020 | 370 | 0.210 |
Why?
|
| Adipocytes, White | 1 | 2022 | 34 | 0.210 |
Why?
|
| Pyrvinium Compounds | 1 | 2021 | 7 | 0.210 |
Why?
|
| Cell Cycle Proteins | 4 | 2021 | 2045 | 0.210 |
Why?
|
| Cell Movement | 5 | 2020 | 2466 | 0.200 |
Why?
|
| Cell Survival | 5 | 2022 | 3045 | 0.200 |
Why?
|
| Phosphofructokinase-2 | 1 | 2021 | 38 | 0.200 |
Why?
|
| Sirtuins | 1 | 2021 | 44 | 0.200 |
Why?
|
| Intra-Abdominal Fat | 1 | 2022 | 95 | 0.200 |
Why?
|
| Anthelmintics | 1 | 2021 | 69 | 0.200 |
Why?
|
| Calcium Channels | 1 | 2022 | 197 | 0.190 |
Why?
|
| Immunoglobulin E | 1 | 2021 | 163 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 4938 | 0.190 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 11538 | 0.190 |
Why?
|
| RNA Interference | 3 | 2019 | 1408 | 0.190 |
Why?
|
| RNA Splicing Factors | 1 | 2021 | 153 | 0.190 |
Why?
|
| Prostaglandin D2 | 1 | 2020 | 26 | 0.190 |
Why?
|
| Anthracenes | 1 | 2020 | 48 | 0.190 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 28 | 0.190 |
Why?
|
| Oligomycins | 1 | 2020 | 9 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 5178 | 0.190 |
Why?
|
| Actins | 2 | 2020 | 608 | 0.190 |
Why?
|
| Implants, Experimental | 1 | 2020 | 17 | 0.190 |
Why?
|
| Adiposity | 1 | 2022 | 237 | 0.180 |
Why?
|
| Chemoradiotherapy | 2 | 2021 | 1946 | 0.180 |
Why?
|
| Dasatinib | 1 | 2023 | 862 | 0.180 |
Why?
|
| HEK293 Cells | 3 | 2020 | 1489 | 0.180 |
Why?
|
| Liposomes | 1 | 2022 | 684 | 0.180 |
Why?
|
| Female | 22 | 2024 | 141928 | 0.180 |
Why?
|
| Organoids | 1 | 2022 | 287 | 0.170 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 62 | 0.170 |
Why?
|
| Necrosis | 2 | 2019 | 580 | 0.170 |
Why?
|
| Muscular Atrophy | 1 | 2020 | 105 | 0.170 |
Why?
|
| Rotarod Performance Test | 1 | 2019 | 26 | 0.170 |
Why?
|
| Adenosine | 1 | 2021 | 289 | 0.170 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2019 | 39 | 0.170 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2021 | 363 | 0.170 |
Why?
|
| 3T3-L1 Cells | 1 | 2019 | 77 | 0.170 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2019 | 46 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 129 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2018 | 1439 | 0.170 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 123 | 0.170 |
Why?
|
| Probiotics | 1 | 2021 | 228 | 0.170 |
Why?
|
| Gastroesophageal Reflux | 1 | 2021 | 334 | 0.170 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 986 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 2232 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 5 | 2015 | 3981 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2020 | 251 | 0.160 |
Why?
|
| Biofilms | 1 | 2020 | 199 | 0.160 |
Why?
|
| Transcription, Genetic | 3 | 2021 | 3154 | 0.160 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 239 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 129 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 2359 | 0.160 |
Why?
|
| U937 Cells | 1 | 2018 | 171 | 0.160 |
Why?
|
| Proteasome Inhibitors | 1 | 2019 | 231 | 0.160 |
Why?
|
| Oxaloacetic Acid | 1 | 2017 | 2 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 1331 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2019 | 199 | 0.150 |
Why?
|
| Tumor Hypoxia | 1 | 2017 | 24 | 0.150 |
Why?
|
| Tubulin Modulators | 1 | 2017 | 65 | 0.150 |
Why?
|
| Androgens | 1 | 2020 | 511 | 0.150 |
Why?
|
| Carbon | 3 | 2024 | 149 | 0.150 |
Why?
|
| Lactones | 1 | 2017 | 94 | 0.150 |
Why?
|
| Nitrogen | 1 | 2017 | 162 | 0.150 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 1519 | 0.150 |
Why?
|
| Adipocytes | 1 | 2019 | 305 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2022 | 686 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 5112 | 0.140 |
Why?
|
| Organs at Risk | 1 | 2019 | 514 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2020 | 428 | 0.140 |
Why?
|
| Cell Polarity | 1 | 2018 | 208 | 0.140 |
Why?
|
| Pentose Phosphate Pathway | 2 | 2017 | 69 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2016 | 78 | 0.140 |
Why?
|
| RNA | 1 | 2021 | 1013 | 0.140 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 85 | 0.140 |
Why?
|
| Tumor Burden | 3 | 2021 | 1987 | 0.140 |
Why?
|
| Micelles | 1 | 2015 | 34 | 0.140 |
Why?
|
| A549 Cells | 3 | 2021 | 124 | 0.140 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2017 | 585 | 0.140 |
Why?
|
| Microtubules | 1 | 2017 | 270 | 0.140 |
Why?
|
| Monocytes | 1 | 2020 | 788 | 0.140 |
Why?
|
| Cell Separation | 1 | 2018 | 612 | 0.140 |
Why?
|
| Random Allocation | 1 | 2017 | 703 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 548 | 0.140 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 5159 | 0.130 |
Why?
|
| Disease Progression | 4 | 2021 | 6682 | 0.130 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2015 | 80 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 778 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2021 | 1491 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2020 | 1549 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2020 | 769 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2018 | 974 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 2027 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 878 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 1443 | 0.120 |
Why?
|
| Vitamin E | 1 | 2014 | 136 | 0.120 |
Why?
|
| Alleles | 1 | 2020 | 2437 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2020 | 672 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 592 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2015 | 886 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 852 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2015 | 305 | 0.120 |
Why?
|
| Th2 Cells | 1 | 2014 | 257 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2011 | 726 | 0.110 |
Why?
|
| Th1 Cells | 1 | 2014 | 250 | 0.110 |
Why?
|
| Heart | 1 | 2019 | 1223 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5319 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 992 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Annona | 1 | 2012 | 1 | 0.110 |
Why?
|
| Mycoplasma | 1 | 2011 | 14 | 0.110 |
Why?
|
| Inflammation | 2 | 2020 | 2522 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 5437 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 1756 | 0.110 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2011 | 30 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2012 | 86 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2022 | 2295 | 0.100 |
Why?
|
| Blood Cells | 1 | 2012 | 127 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2011 | 34 | 0.100 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2011 | 87 | 0.100 |
Why?
|
| Mice, SCID | 3 | 2021 | 1869 | 0.100 |
Why?
|
| Lipopeptides | 1 | 2011 | 114 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 119 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2012 | 110 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2018 | 3033 | 0.100 |
Why?
|
| Male | 15 | 2022 | 123000 | 0.100 |
Why?
|
| Pancytopenia | 1 | 2011 | 120 | 0.100 |
Why?
|
| Radiation Dosage | 2 | 2016 | 1014 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2015 | 1038 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2017 | 1129 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 2488 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2007 | 4233 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2012 | 266 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 4757 | 0.090 |
Why?
|
| Radiation Protection | 1 | 2011 | 205 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4557 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 1538 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2012 | 215 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 336 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 6089 | 0.090 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8865 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1053 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 3639 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2017 | 1313 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 1121 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2022 | 4143 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 709 | 0.080 |
Why?
|
| Berberidaceae | 1 | 2008 | 1 | 0.080 |
Why?
|
| Rhizome | 1 | 2008 | 6 | 0.080 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 32 | 0.080 |
Why?
|
| Genes, ras | 1 | 2011 | 667 | 0.080 |
Why?
|
| Intestines | 1 | 2013 | 686 | 0.080 |
Why?
|
| Gene Knockout Techniques | 2 | 2019 | 276 | 0.080 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2007 | 17 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 1 | 2008 | 249 | 0.080 |
Why?
|
| Proteome | 1 | 2012 | 561 | 0.080 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 905 | 0.080 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2022 | 388 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2054 | 0.080 |
Why?
|
| DNA, Mitochondrial | 2 | 2019 | 311 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2019 | 4078 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2007 | 1008 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 2138 | 0.080 |
Why?
|
| Fibrosis | 2 | 2022 | 793 | 0.080 |
Why?
|
| Lectins | 1 | 2007 | 151 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.080 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 5767 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2020 | 6150 | 0.070 |
Why?
|
| Perineum | 1 | 2007 | 107 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2021 | 9180 | 0.070 |
Why?
|
| Radiography | 1 | 2011 | 1904 | 0.070 |
Why?
|
| Time Factors | 2 | 2020 | 12926 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 548 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.070 |
Why?
|
| Polyesters | 2 | 2016 | 53 | 0.070 |
Why?
|
| Amino Acid Motifs | 1 | 2007 | 392 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6009 | 0.070 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2007 | 168 | 0.070 |
Why?
|
| Stem Cells | 1 | 2013 | 1213 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 397 | 0.070 |
Why?
|
| Tyrosine | 1 | 2007 | 498 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2021 | 5395 | 0.070 |
Why?
|
| Glioma | 1 | 2016 | 1963 | 0.070 |
Why?
|
| Drug Compounding | 2 | 2015 | 70 | 0.070 |
Why?
|
| Immunity, Innate | 2 | 2020 | 677 | 0.060 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 3168 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 702 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2015 | 4804 | 0.060 |
Why?
|
| Vitamin B 6 | 1 | 2024 | 19 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3343 | 0.060 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2024 | 83 | 0.060 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2023 | 28 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 2173 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2015 | 562 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2024 | 163 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2021 | 1764 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.060 |
Why?
|
| beta Catenin | 1 | 2007 | 688 | 0.060 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2022 | 34 | 0.060 |
Why?
|
| Cathepsin B | 1 | 2022 | 32 | 0.060 |
Why?
|
| Binding Sites | 1 | 2007 | 2171 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 2314 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 862 | 0.050 |
Why?
|
| Cytokines | 1 | 2011 | 2809 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 2315 | 0.050 |
Why?
|
| Cystine | 1 | 2022 | 34 | 0.050 |
Why?
|
| Prognosis | 4 | 2017 | 21713 | 0.050 |
Why?
|
| Uncoupling Protein 1 | 1 | 2022 | 33 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2022 | 104 | 0.050 |
Why?
|
| Phospholipids | 1 | 2022 | 177 | 0.050 |
Why?
|
| Carboxylic Acids | 1 | 2022 | 57 | 0.050 |
Why?
|
| Global Health | 1 | 2007 | 657 | 0.050 |
Why?
|
| Gastric Acid | 1 | 2021 | 42 | 0.050 |
Why?
|
| Dimerization | 1 | 2022 | 304 | 0.050 |
Why?
|
| Enzyme Activators | 1 | 2021 | 20 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2007 | 1620 | 0.050 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2021 | 44 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 15862 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 261 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 155 | 0.050 |
Why?
|
| Ataxia Telangiectasia | 1 | 2021 | 62 | 0.050 |
Why?
|
| Jejunum | 2 | 2013 | 216 | 0.050 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2021 | 76 | 0.050 |
Why?
|
| Ceruletide | 1 | 2020 | 27 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2022 | 309 | 0.050 |
Why?
|
| Oligonucleotide Probes | 1 | 2020 | 130 | 0.050 |
Why?
|
| Octamer Transcription Factors | 1 | 2020 | 19 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2021 | 5710 | 0.050 |
Why?
|
| Quality Control | 1 | 2022 | 457 | 0.050 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2020 | 52 | 0.050 |
Why?
|
| Lysine | 1 | 2022 | 422 | 0.050 |
Why?
|
| Methotrexate | 1 | 2023 | 999 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2020 | 118 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 249 | 0.050 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2020 | 81 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 332 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 443 | 0.040 |
Why?
|
| Methylation | 1 | 2021 | 597 | 0.040 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Splenectomy | 1 | 2020 | 158 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 332 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 144 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 4053 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 430 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 149 | 0.040 |
Why?
|
| Biopsy | 1 | 2007 | 3443 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2006 | 1818 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 467 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 249 | 0.040 |
Why?
|
| Bone Marrow | 2 | 2020 | 2358 | 0.040 |
Why?
|
| Threonine | 1 | 2019 | 161 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 115 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 216 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2017 | 2450 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 904 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12221 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 7548 | 0.040 |
Why?
|
| Interleukins | 1 | 2020 | 325 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 842 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2020 | 267 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 32848 | 0.040 |
Why?
|
| Hydroxybenzoates | 1 | 2017 | 4 | 0.040 |
Why?
|
| Gene Expression | 2 | 2018 | 3570 | 0.040 |
Why?
|
| Drug Design | 1 | 2020 | 375 | 0.040 |
Why?
|
| Serine | 1 | 2019 | 388 | 0.040 |
Why?
|
| Digoxin | 1 | 2017 | 63 | 0.040 |
Why?
|
| Bortezomib | 1 | 2019 | 543 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 1070 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 1082 | 0.040 |
Why?
|
| Deoxyglucose | 1 | 2017 | 115 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2019 | 429 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 204 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2018 | 798 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2019 | 413 | 0.040 |
Why?
|
| Stilbenes | 1 | 2016 | 86 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2019 | 445 | 0.030 |
Why?
|
| Excipients | 1 | 2015 | 17 | 0.030 |
Why?
|
| Diffusion | 1 | 2015 | 88 | 0.030 |
Why?
|
| Pancreatectomy | 1 | 2020 | 652 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 2012 | 750 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2020 | 1944 | 0.030 |
Why?
|
| Drug Stability | 1 | 2015 | 105 | 0.030 |
Why?
|
| Calcium | 1 | 2022 | 1537 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 607 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 1914 | 0.030 |
Why?
|
| Materials Testing | 1 | 2015 | 116 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 133 | 0.030 |
Why?
|
| Capecitabine | 1 | 2016 | 388 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 621 | 0.030 |
Why?
|
| Emulsions | 1 | 2014 | 82 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2019 | 1234 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 697 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2016 | 485 | 0.030 |
Why?
|
| Hemolysis | 1 | 2014 | 127 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 2086 | 0.030 |
Why?
|
| Polymers | 1 | 2015 | 223 | 0.030 |
Why?
|
| Mutation | 3 | 2021 | 15179 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 550 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 13658 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 483 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 6550 | 0.030 |
Why?
|
| United States | 2 | 2021 | 15433 | 0.030 |
Why?
|
| DNA Repair | 1 | 2021 | 1872 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.030 |
Why?
|
| DNA Breaks | 1 | 2013 | 39 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Endotoxins | 1 | 2013 | 96 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 2084 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 1678 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 938 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 1959 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 2012 | 30 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3890 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 1380 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 1643 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 6100 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 3438 | 0.030 |
Why?
|
| Filgrastim | 1 | 2012 | 191 | 0.030 |
Why?
|
| Benzylamines | 1 | 2012 | 105 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 1226 | 0.020 |
Why?
|
| Phenotype | 2 | 2017 | 6295 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 7551 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 1249 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 760 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 503 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3719 | 0.020 |
Why?
|
| Purines | 1 | 2011 | 273 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 663 | 0.020 |
Why?
|
| Peptides | 1 | 2015 | 1479 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2020 | 2967 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2015 | 1026 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2012 | 749 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.020 |
Why?
|
| Bacteria | 1 | 2013 | 611 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 10001 | 0.020 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2007 | 7 | 0.020 |
Why?
|
| Cricetulus | 1 | 2007 | 205 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2007 | 75 | 0.020 |
Why?
|
| CHO Cells | 1 | 2007 | 311 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 3869 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 4975 | 0.020 |
Why?
|
| Cricetinae | 1 | 2007 | 706 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6207 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 591 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 2927 | 0.020 |
Why?
|
| Lung | 1 | 2017 | 3151 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3536 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 1081 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 6086 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3472 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 2104 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2017 | 3518 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 9244 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 77950 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 4844 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 21445 | 0.010 |
Why?
|
| Middle Aged | 2 | 2021 | 86204 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 31252 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2006 | 2074 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 2216 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 29902 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 70117 | 0.010 |
Why?
|